Skip to search formSkip to main contentSkip to account menu

Ibrutinib

Known as: 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one, 2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)- 
An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration… 
National Institutes of Health

Related topics

Related topics

6 relations
Ibrutinib 140 MG Oral CapsuleIbrutinib 140 MG Oral Capsule [Imbruvica]NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Narrower (1)

Imbruvica

Broader (1)

PCI 32765

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic…
BACKGROUND: Chronic lymphocytic leukemia (CLL) is one of the most common lymphoid malignancies, accounting for ~11% of all… 
2018
2018
Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL).
7502Background: Ibr, a first-in-class, once-daily BTK inhibitor, is approved in the US and EU for CLL treatment, including del17p… 
Highly Cited
2017
Highly Cited
2017
Synthesis, Pharmacokinetics, Pharmacodynamics, Dosing, Stability, Safety and Efficacy of Orphan Nano Drugs to Treat High Cholesterol and Related Conditions and to PreventCardiovascular Disease Under…
Orphan Nano drugs such as Rituxan, Revlimid, Soliris, Afinitor, Tasigna, Velcade, Avonex, Alimta, Yervoy, Sprycel, Rebif… 
2017
2017
CD19 CAR-T cells combined with ibrutinib to induce complete remission in CLL.
7509Background: Immunotherapy with anti-CD19 CART cells induces complete remission (CR) in the minority of patients with CLL, but… 
2017
2017
Combined Venetoclax and Ibrutinib for Patients with Previously Untreated High-Risk CLL, and Relapsed/Refractory CLL: A Phase II Trial
Background: Ibrutinib (IBR), a BTK inhibitor is approved for patients (pts) with CLL. Venetoclax (VEN), a BCL2 inhibitor is… 
Review
2016
Review
2016
Autoimmune hemolytic anemia (AIHA) associated with chronic lymphocytic leukemia in the current era of targeted therapy.
2016
2016
Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia
Progressive multifocal leukoencephalopathy (PML) is a devastating neurological disease observed nearly exclusively in… 
2015
2015
Comparing Single-Agent Ibrutinib, Bendamustine Plus Rituximab (BR) and Ibrutinib Plus BR in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): An…
Introduction In 2 large phase 3 trials of patients (pts) with relapsed or refractory (R/R) CLL/SLL, single-agent ibrutinib (ibr… 
Review
2014
Review
2014
Ibrutinib in chronic lymphocytic leukemia and B cell malignancies
Abstract Recent clinical data suggest remarkable activity of ibrutinib, the first-in-class covalent inhibitor of Bruton's… 
2013
2013
Ibrutinib In Combination With Rituximab (iR) Is Well Tolerated and Induces a High Rate Of Durable Remissions In Patients With High-Risk Chronic Lymphocytic Leukemia (CLL): New, Updated Results Of a…
![Graphic][1] The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is a promising new targeted therapy for patients with mature… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)